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1Chapter
Antimicrobial Resistance in 
Escherichia coli
Mario Galindo-Méndez
Abstract
In the last decades, antimicrobial resistance has become a global threat to public 
health systems worldwide. Among those bacteria that pose the greatest threat to 
human health because of its growing resistance to antibiotics are the members of 
the Enterobacteriaceae family, particularly Escherichia coli and Klebsiella spp. Among 
the different antibiotic-resistant mechanisms developed by bacteria, the ones found 
in Enterobacteriaceae are more diverse than those in other families and include 
resistance to different antibiotic groups, advantages that partially explain why these 
microorganisms are among the most common causes of antibiotic-resistant bacte-
rial infections in humans. Due to the continuously increasing number of infections 
caused by multidrug-resistant E. coli due to its ease of transmission via the fecal-
oral route among humans and from environmental sources, the understanding 
of the epidemiology of these strains and their mechanisms of resistance are key 
components in the fight against these infections.
Keywords: antimicrobial resistance, multidrug resistance, antibiotics,  
Escherichia coli, Enterobacteriaceae
1. Introduction
Escherichia coli is one of the most studied bacteria in the world and is arguably 
the best understood of all model microorganisms [1]. In the context of human and 
animal ecology, this microorganism participates as both a commensal of the gut, 
being one the first bacterial species to colonize it right after birth [2], and one of the 
most important human and animal pathogens, being able to cause intestinal and 
extra-intestinal infections. In humans, E. coli is the most frequent cause of urinary 
tract infections and has been identified as the causative agent of disease in practi-
cally every anatomical site of the human body, causing appendicitis, pneumonia, 
bloodstream, gastrointestinal infections, skin abscesses, intra-amniotic and puer-
peral infection in pregnant women, meningitis and endocarditis. Furthermore, E. 
coli can cause both community-acquired infections and health care-related infec-
tions, and is able to cause disease in all age groups.
Since the introduction of penicillin in the 1940s, which started the era of 
antibiotics, these agents have been recognized as one of the greatest advances in 
modern medicine and a turning point in human history. In 1900, infectious disease 
was a leading cause of death; in 2000, infectious diseases were responsible for only 
a small percentage of deaths in developed nations [3]. Unfortunately for humans, 
bacteria have evolved different mechanisms that have rendered them resistant to 
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antibiotics, to the point that since not long ago antimicrobial resistance has become 
a global threat to public health systems worldwide.
The ability of bacteria to develop resistance against antibiotics began soon after 
their introduction, as penicillin resistance by S. aureus was identified just a few 
years after its introduction in hospitalized patients [4]. In the case of E. coli, resis-
tance against antibiotics has been steadily increasing since the first reported cases 
and, due to its impact in human health, is now included, along with the rest of the 
Enterobacteriaceae family, in the World Health Organization’s (WHO) list of the 12 
families of bacteria that pose the greatest threat to human health [5].
The contribution of E. coli to the antimicrobial resistance phenomenon should 
be analyzed under two different, but complementary, contexts that at some point 
meet in one common issue: a broad impact on human health. These two perspec-
tives include the increasing number of infections worldwide caused by multidrug-
resistant E. coli strains per se and the ability of this bacterium to transmit its 
genetic-resistant traits to other bacteria. E. coli has evolved these two attributes that 
have made this microorganism such a key player in the antibiotic resistance pan-
demic due to its ease of transmission among humans and from animals to humans 
via the fecal-oral route. Secondly, the microorganism’s ability to colonize the gut of 
humans and animals allow it to be in close interaction with an abounding number 
of different bacteria, interaction that grant E. coli the duality to behave as a donor 
of genetic material to other bacteria and the ability to acquire resistance genes from 
other microorganisms.
This chapter describes the human actions that have contributed to the develop-
ment of E. coli resistance to antibiotics, including the major impact of hygiene on 
the transmission and maintenance of its multidrug-resistant strains, and the known 
mechanisms developed by this organism to resist the actions of commonly used 
antibiotics.
2. Onset and spread of E. coli resistance to antibiotics
The emergence of antibacterial resistance in E. coli and other bacteria is multi-
factorial, but has paralleled the incorporation of these agents into the therapeutic 
arsenal in human and veterinary medicine. Data show that E. coli present the 
highest rates of resistance against those antibiotics that have been in use the longest 
time [6], as is evidenced by the high resistance rate worldwide against sulfonamides 
[7], whose use in humans started in the 1930s and its first E. coli-resistant clones 
were identified as early as 1950 [6]. Additionally, it is of no coincidence that those 
regions of the world with the highest consumption of antibiotics are low- to mid-
income countries (Table 1), whose antibiotic-resistant rates are higher than those 
found in high-income nations.
Antibiotic resistance (AR) is largely believed to be the sole result of human 
activity and antibiotic chemotherapy; however, genomic studies of human bacterial 
commensals and environmental bacteria have revealed the presence of consider-
able numbers of resistance determinants within their genomes [9] that were not 
acquired from horizontal transmission and predated the clinical introduction of 
antibiotics. This type of AR is known as intrinsic resistance and provides a selec-
tive benefit for the producing strains by inhibiting or eliminating other bacteria 
competing for resources. Intrinsic resistance differentiates from the newly devel-
oped extrinsic antibiotic resistance in that in the former there is no contribution of 
human activities and the latter is mainly driven by antibiotic selection pressure [10]. 
In the current era of increasing AR and lack of new antibacterial agents, the study 
of intrinsic resistance becomes highly attractive as a new mechanism to counteract 
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bacterial resistance, as inhibition of elements that comprise the intrinsic resistome 
renders bacteria hyper-susceptible to antibiotics [11]. In the case of Gram-negative 
bacteria, like E. coli, two major contributors to the bacterium intrinsic resistance are 
its outer membrane, which is impermeable to many molecules, and its expression of 
numerous efflux pumps, that effectively reduce the intracellular concentration of 
certain antibiotics [12].
The acquired, or extrinsic, and continuously increasing resistance of E. coli to 
antibiotics is already considered a major public health problem around the world. 
In 2018, more than half of the Escherichia coli isolates reported to the European 
Centre for Disease Prevention and Control were resistant to at least one antimicro-
bial group under surveillance, and combined resistance to several antimicrobial 
groups was frequent [13]; in the United States in 2017, the national prevalence of 
extended spectrum β-lactamases (ESBL)-producing E. coli strains isolated from 
urinary tract infections (UTI) was 15.7%, whereas levofloxacin and trimethoprim-
sulfamethoxazole-resistant rates were ≥24% among all isolates [14]. In developing 
countries the situation worsens, as reported by national surveillance data from 
Mexico, China and Turkey, where E. coli-resistant strains has been shown to have a 
prevalence >40% to cephalosporins, quinolones and trimethoprim/sulfamethoxa-
zole (TSX), drugs widely used around the world to empirically treat bacterial 
infections (Table 2).
During 1945, just a few years after the introduction into clinical practice of peni-
cillin, Alexander Fleming warned the world about antibiotic overuse, warning that 
became reality a few years later when the first S. aureus strain was reported to be 
resistant to penicillin. Several human activities have been identified as key drivers 
of the current AR crisis, but it has been demonstrated that the overuse of antibiotics 
clearly influences the evolution of resistance [18]. The reported actions that have 
led to the overuse of antibiotics are multifactorial and include different players in 
different industries such as the health, the livestock and the pharmaceutical indus-
tries. Examples of these actions comprise inappropriate prescription of antibiotics 
by healthcare providers, extensive use of antibiotics in livestock and fish farming, 
patients not following antibiotic treatment regimes, poor hygiene, bacterial muta-
tions and lack of new antibiotics developed [19].
2.1 Overuse/inappropriate prescribing
One of the most significant factors that have contributed to the current anti-
bacterial resistance crisis is the rapid evolution of bacteria under selective anti-
biotic pressure, since a continuous interaction between any given antibiotic and 
bacteria is an important aspect for the increase in multidrug-resistant strains [20]. 
Country Daily doses per 1000 inhabitants/day (% of total) [8]
Mongolia 64.4
Iran 38.8
Turkey 38.2
Sudan 35.3
Serbia 31.6
Montenegro 29.3
Romania 28.5
Table 1. 
Countries with the highest antibiotic consumption in the world.
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Unfortunately, overuse and inappropriate prescription of these drugs are two large 
contributors to such issue. In any given antibiotic treatment against a bacterial infec-
tion, susceptible bacteria will be killed; if properly targeted, the pathogenic micro-
organism will be eradicated; however, along infecting bacteria, those members of 
the individual’s microbiota, sensitive to the antibiotic in use, will also be wiped out. 
In case resistant microorganisms exist, either belonging to the normal microbiota 
or the pathogenic microorganisms being targeted, these survivors will replicate and 
will become the prevailing strain within the respective anatomical site.
The discovery and use of antibiotics have revolutionized the field of medicine 
and saved millions of lives each year; unfortunately, seen as the “miracle drug,” 
healthcare providers and patients around the world have abused their use. Despite 
the marked increase of infections caused by multidrug-resistant bacteria around 
the world, the global response to this crisis has been inadequate, as people not 
only continue to misuse antibiotics but have continuously increased their abuse. 
Using a global database of antibiotic sales, Klein et al. [21] found that the antibi-
otic consumption rate around the world increased dramatically from 11.3 daily 
doses/1000 inhabitants per day to 15.7, an increase of 39%, between 2000 and 
2015. In this same study, it was reported that the mean antibiotic consumption rate 
was primarily driven by the consumption in low- and mid-income countries, as no 
coincidence present the highest prevalence of multi drug-resistant bacteria-related 
infections. To make matters worse, the consumption of last-resort antibiotics such 
as carbapenems and colistin is also on the rise [21], situation that is consistent with 
the appearance of E. coli-resistant strains to these agents. To date, resistance of this 
organism to carbapenems is rare, with its prevalence depending on the area of the 
world under study, but not exceeding 3% [22]. However, in the future, an increase 
of resistance to this agent might be seen in E. coli, as the enzymes responsible for its 
hydrolysis, and thus inactivation, carbapenemases, are encoded mainly on plas-
mids, and are highly transmissible [23].
A key contributor to the increasing selective pressure of antibiotics is their 
overprescription. Recent data indicates that over 70% of prescribed antibiotics by 
primary care providers in the United States are inappropriate, the majority of which 
are for acute respiratory tract infections [24]; unfortunately, this rate of antibiotic 
misuse is probably a situation found in most countries. Coincidently, ciprofloxacin, 
one of the two most likely antibiotic to be prescribed inappropriately [24] is one to 
which E. coli present the highest rates of resistance around the world [15–17].
In addition to the contribution of the abuse of antibiotics to the selection of 
resistance, Zhang et al. [25] found epidemiological evidence that antibiotic resis-
tance and E. coli diarrheagenic virulence phenotypes might be partially linked. They 
found that subjects with diarrhea had more frequent use of antibiotics before their 
onset of symptoms, linkage that might be explained as antibiotics might disrupt the 
intestinal microbiota, allowing overgrowth of resistant pathogens [25].
Country Resistance rates (%)
Cephalosporins Quinolones TSX
Mexico [15] 54.4 59.0 62.1
China [16] 52.4 69.8 ND
Turkey [17] 40.7 47.2 58.0
ND: not done.
Table 2. 
Escherichia coli antibiotic resistance rates to different antibiotics.
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2.2 Use of antibiotics in livestock
Antibiotics are used in livestock to treat clinical disease, to prevent and control 
common disease events, and to enhance animal growth [26]. Unfortunately, this use 
of antibiotics has favored spread and persistence of resistant bacteria in humans by 
means of two different mechanisms: (a) human ingestion of antibiotics by means 
of the antibiotic-contaminated meat that enters the body and induces selective 
pressure on the host’s microbiota and (b) resistant bacteria found in the gut of food 
animals are transmitted to humans via contaminated meat.
When livestock are treated or are provided with antibiotics, these agents 
exercise the same selective pressure on their microbiota as when humans ingest 
these drugs; thus, overuse of antibiotics on food animals has led to a high coloniza-
tion rate of intestinal bacteria, including members of the Enterobacteriaceae family, 
such as E. coli and Klebsiella spp., that become resistant to different antimicrobials. 
Different studies around the world have shown that ready-to-eat animal products 
are contaminated with E. coli strains resistant to different kinds of antibiotics, 
mainly to β-lactams by means of the bacterial production of extended spectrum 
β-lactamases (ESBL) [27, 28]. These studies show that animal meat contaminated 
with E. coli-resistant strains is far more prevalent in developing than in developed 
nations, probably due to different hygiene habits; German studies have reported 
a prevalence of ESBL-contaminated meat of 24.1% [27], whereas in Mexico this 
prevalence has been reported to be above 60.0% [28]. E. coli strains isolated in 
meat have also shown resistance to other antibiotics, including to last-resort ones 
such as carbapenems [29] and colistin [30]. If this contaminated meat is ingested 
undercooked by humans, gut colonization is likely, establishing a reservoir for 
future antibiotic-resistant infections, as Ruppé et al. have shown that people with 
high gut colonization rates of ESBL-producing E. coli strains present higher risk to 
develop urinary tract infections with these clones than patients with no ESBL gut 
colonization [31].
Figure 1 shows a resumed representation of the main reservoirs, including 
livestock, of antibiotic-resistant E. coli and their interaction with humans.
2.3 Hygiene/fecal colonization
Higher consumption of antibiotics in unprivileged areas of the world plays a key 
role in the emergence and maintenance of antimicrobial resistance due to selective 
pressure by these agents on resident microbiota. However, studies have shown that 
inhabitants of these areas can be highly colonized with antibiotic-resistant E. coli 
strains despite not being in contact with antibiotics for 3–6 months [28], indicat-
ing that additional factors play important roles in the increased prevalence of AR 
worldwide. Global evidence suggests that elements in people’s environment such as 
poor waste, non-potable drinking water, housing overcrowding and lack of hygiene 
facilitate the development and transmission of resistant bacteria [32].
The ability of E. coli to colonize different environments, including the gut of 
humans and animals, has provided this organism with the evolutionary advantage 
to acquire antibiotic resistance traits from other bacteria within its environment, 
as well as to be easily transmitted via the fecal-oral route. The gut microbiota of 
humans can harbor more than 1000 different antibiotic-resistant genes [33] and 
transmission of these traits among gut commensals is a constant phenomenon. 
Major examples of the transference of resistance genes between environmental 
bacteria, including gut commensals, and human pathogens, are the blaCTX-M 
genes, which is the most prevalent ESBL gene in E. coli and Klebsiella spp., and 
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the OXA-48-type carbapenem-hydrolyzing β-lactamase genes, which are increas-
ingly reported in Enterobacteriaceae around the globe. The potential origin of the 
blaCTX-M genes was identified in the chromosomal DNA of various environmental 
Kluyvera species [34], whereas that of OXA-48 was found to originate from the 
waterborne, environmental Shewanella species [35].
As many antibiotic resistance genes are associated with elements such as 
plasmids or transposons, and while the transfer of these elements may also occur 
through transformation or transduction, conjugation is often considered as the 
most likely responsible mechanism for the transmission of these traits [36]. The 
aforementioned ESBL and carbapenemase genes are primary examples of resistant 
genes with high impact on human health that have spread between bacteria via 
plasmid conjugation. Studies in China [37] have demonstrated that transmission 
via conjugation of ESBL genes in E. coli do occur even in the food chain, situation 
that partially explain the high fecal prevalence of ESBL-producing E. coli around 
the world.
The gut of humans and animals is a major reservoir of antibiotic-resistant E. coli 
and shedding of these strains through the feces of colonized individuals, livestock 
and domestic animals allows them to reach humans via contaminated water and 
food (see Figure 1). Human fecal colonization by antibiotic-resistant E. coli strains 
present the highest rates in deprived areas of the world, situation that begins since 
birth. Whereas in high-income nations the prevalence of E. coli strains resistant to 
antibiotics colonizing the gastrointestinal system of neonates is low [38], in low-
income countries the prevalence of E. coli strains resistant to antibiotics such as tet-
racycline, ampicillin and trimethoprim/sulfamethoxazole exceeds 50% [39]. Fecal 
colonization of humans by resistant E. coli is on the rise around the world since the 
mid-2000s and the situation has worsened as fecal colonization by strains resistant 
to last-resource antibiotics, such as colistin, has been recently reported in different 
countries [40, 41]. As the prevalence of fecal colonization by these E. coli strains 
increase, so will the number of human infections caused by them, as it has been 
previously shown that fecal colonization with resistant microorganisms increases 
the risk factor of developing urinary tract infections by a factor of 13.0 [31].
Antibiotic consumption has contributed to the selection of resistance and is 
largely accepted as one of the major drivers of AR development; however, the high 
Figure 1. 
Reservoirs of antibiotic-resistant E. coli and their interaction with humans. Arrows show the E. coli flux from 
the different reservoirs.
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prevalence of antibiotic resistance around the world, especially in low- and mid-
income countries, can be more likely attributed to the dissemination and mainte-
nance of resistant clones via poor sanitation and lack of hygiene habits [32]. Ingestion 
of contaminated food and water, close contact with colonized animals and household 
members and abundance of flies are factors that contribute to the transmission of kl 
E. coli strains. As these conditions are considerably less frequent in developed areas 
of the world, this situation partially explains the reduced prevalence of these strains 
in these nations. However, due to the current globalization, resistant strains can 
easily be transmitted from one country to another. In a large cohort study of Dutch 
travelers to regions of the world with high prevalence of ESBL-producing bacteria, 
34.3% subjects who were ESBL negative before travel had acquired these clones dur-
ing their time abroad, with the highest number of acquisitions being among those 
who traveled to southern Asia, and remained colonized at 12 months after return 
[42]. Additionally, this same study showed that the estimated probability of onward 
transmission within households was 12%. Similar results were reported in a study in 
Spain, in which up to 66% of the isolates from patients with ESBL-producing E. coli 
infections were indistinguishable from those isolated from fecal samples from their 
household members [43]. These results indicate that acquisition of E. coli-resistant 
clones during travel is high and that transmission between household members can 
maintain such clones in the community for long periods of time.
As anthropogenic activities largely shape the resistome of different environ-
ments, transmission of resistant genes between bacteria in a community can be 
influenced by its contamination with human and animal feces and its impact is 
largely driven not by the presence of resistant bacteria but rather from the presence 
of human-related mobile resistance genes [44]. If poor sanitation, manifested by 
fecal contamination, of a given community is the key to transmit and maintain 
resistant clones, the reduction of antibiotic consumption will not be sufficient 
to control antimicrobial resistance. Thus, strategies to control the AR pandemic 
should also include improving sanitation conditions in all parts of the world.
3. Antibiotic resistance mechanisms
Few microorganisms have shown the ability to develop resistance to as many 
classes of antibiotics as the Enterobacteriaceae. Of the large list of bacterial genus 
that belong to this family, E. coli is only surpassed by Klebsiella in the number of 
human infections associated to multidrug-resistant bacteria [15–17, 27] and the 
past two decades have witnessed major increases in the emergence and spread 
of E. coli resistance strains to major classes of antibiotics such as β-lactams, 
quinolones, aminoglycosides, sulfonamides and fosfomycin. Unfortunately, this 
resistance has spread to last resource antibiotic classes such as the polymyxins and 
carbapenems. The following sections will briefly described the resistance mecha-
nisms developed by E. coli against one of the major antibiotic groups currently 
used in the treatment against this organism: the β-lactams.
3.1 Resistance to β-lactams
Antibiotics belonging to the β-lactams class share a common feature: a three-
carbon and one-nitrogen ring (beta-lactam ring), which is the molecular constitu-
ent responsible for the bacteriolytic mechanism of action of these agents against 
bacteria. β-Lactams act by inhibiting the bacterial synthesis of peptidoglycan, a 
vital constituent of the microorganism cell wall. The targets for the actions of beta-
lactam antibiotics are known as penicillin-binding proteins (PBPs).
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Bacteria have evolved different mechanisms of resistance against β-lactams:  
(a) Inactivation of these agents by the production of beta-lactamases; (b) decreased 
penetration of the antibiotic to the target site; (c) alteration of target site PBPs; 
and (d) efflux from the periplasmic space through specific pumping mechanism. 
However, in the case of E. coli, resistance to these antibiotics is mediated by the 
production of a group of enzymes referred as the “β-lactamases.” These enzymes 
are ancient compounds, currently exceeding 2800 unique proteins, which emerged 
from environmental sources [45].
To date, β-lactamases are usually classified based on functional or structural cri-
teria. Currently, the most widely used classification for these enzymes is the Ambler 
structural classification, which is based on sequence similarity, and separates these 
proteins into four classes: the classes A, C, and D of serine-β-lactamases and the 
class B of metallo-β-lactamases [46].
Gram-negative bacteria have evolved the production of different β-lactamases; 
in the case of E. coli, the most important ones from the medical point of view are 
the extended spectrum β-lactamases (ESBL), AmpC β-lactamases (AmpC) and the 
carbapenemases. Each of these groups of enzymes presents different spectrum of 
hydrolytic activity, thus presenting resistance to different types of β-lactams, as 
shown in Table 3.
3.1.1 Extended spectrum β-lactamases (ESBL)
Among the β-lactamases, ESBL are worthy of the attention of the scientific and 
medical community over the last decades because of their increasing prevalence 
as cause of antibiotic-resistant infections around the world. These enzymes can be 
produced by any member of the Enterobacteriaceae, but Klebsiella spp. and E coli are 
the predominant ESBL-producing genus.
ESBL belong mostly to class A of the Ambler classification, are generally 
plasmid encoded and confer resistance to those bacteria that produce them to 
penicillins, first-, second-, and third-generation cephalosporins and monobactams 
(e.g., aztreonam), but cannot hydrolyze cephamycins (cefoxitin) or carbapenems 
(imipenem, meropenem), and are inhibited by β-lactamase inhibitors such as 
clavulanic acid, tazobactam and sulbactam [47].
β-Lactamase Spectrum of activity Inhibition by 
β-lactamase 
inhibitors
Activity against 
broad-spectrum 
cephalosporins
ESBL Penicillins
First to third generation 
cephalosporins
Monobactams
Yes No
AmpC Penicillins
First to third generation 
cephalosporins
Monobactams
No Yes
Carbapenemases
New Delhi 
metallo-β-lactamase
All β-lactams except 
aztreonam
No Yes
Carbapenem-hydrolyzing 
oxacillinase-48
All β-lactams except broad 
spectrum cephalosporins
No Weak
Table 3. 
Spectrum of activity of the major types of β-lactamases produced by Escherichia coli.
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When ESBL were first identified, most ESLB-related infections were caused 
by strains producing the TEM and SHV types. However, since then, ESBL CTX-M 
has emerged as the predominant type, both in humans and animals, in commensal 
organisms and in pathogenic strains and in community and healthcare-associated 
infections. Since the first isolation of SHV- and TEM-producing strains, more than 
100 different variants of each type have been described and all have arisen from the 
original strains; contrary to the SHV and TEM types, CTX-M groups seem to have 
originated from the chromosomally encoded ESBL genes from different Kluyvera 
species [48].
HSV, TEM and CTX-M show different hydrolytic activities against different 
β-lactams. When first identified, SHV β-lactamases proved its activity against peni-
cillins and first generation cephalosporins; as of today, the three sub-groups used 
to classify this group of enzymes present different antibiotic resistance phenotypes: 
(a) subgroup 2b hydrolyze penicillins and early cephalosporins (cephaloridine and 
cephalothin) and are strongly inhibited by clavulanic acid and tazobactam; (b) sub-
group 2br are broad-spectrum β-lactamases that acquired resistance to clavulanic 
acid; and (c) subgroup 2be comprises ESBL that can also hydrolyze one or more 
oxyimino β-lactams (cefotaxime, ceftazidime, and aztreonam) [49]. In the case of 
TEM β-lactamases, the bacteria carrying these genes are able to hydrolyze penicillin 
and first generation cephalosporins such as cephaloridine; furthermore, TEM-1 is 
able to hydrolyze ampicillin at a greater rate than carbenicillin, oxacillin, or cepha-
lothin, and has negligible activity against extended-spectrum cephalosporins [50]. 
Finally, CTX-M enzymes have the property of having potent hydrolytic activity 
against cefotaxime, with CTX-M-producing microorganisms showing cefotaxime 
MICs in the resistant range (>64 μg/ml), while ceftazidime MICs are usually in the 
apparently susceptible range (2 to 8 μg/ml); however, some CTX-M-type ESBLs 
may actually hydrolyze ceftazidime and confer resistance to this cephalosporin; 
aztreonam MICs are variable. CTX-M-type β-lactamases hydrolyze cefepime with 
high efficiency [50].
The exponential global increase in the number of infections caused by ESBL-
producing strains has coincided with the appearance of the CTX-M genes. When 
originally reported, these strains were predominantly found in three geographic 
areas: South America, the Far East, and Eastern Europe. However, due to the 
extremely transferable plasmids which harbor blaCTX-M genes [49], with a fre-
quency of transmission from 10−7 to 10−2 per donor cell [48], these strains are now 
increasingly reported as cause of human infections in every continent, to the point 
that it could be speculated that CTX-M-type ESBLs are now the most frequent ESBL 
type worldwide [50]. An additional factor that has been suggested as a key contrib-
utor to the dissemination of these clones is the frequent co-existence of blaCTX-M 
with genes conferring resistance to other classes of antibiotics like fluoroquinolones 
and aminoglycosides, situation that might lead to high rates of co-selection [51].
To date, over 150 CTX-M types have been identified and described (https://
www.lahey.org/studies/other.asp). These ESBL types have been grouped into five 
clusters (CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25) [52], with each 
cluster presenting different variants, and more variants constantly being described, 
as shown by the recent discovery of two novel ones, named blaCTX-M-14.2 and blaCTX-
M-15.2 [53]. Out of the different CTX-M variants, different reports in different 
continents indicate that blaCTX-M-15, belonging to cluster CTX-M-1, is now the most 
prevalent ESBL in E. coli around the world [54]. The increasing predominance of 
the blaCTX-M-15 allele might be due to the powerful ability of this enzyme to hydro-
lyze different β-lactams, which probably offers the producing bacteria a selective 
advantage, especially when multiple antibiotics are concomitantly or consecutively 
prescribed [53].
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One of the key players in the global dissemination of CTX-M-15-producing 
E. coli strains is clone ST131. A study performed in E. coli ST131 strains isolated 
between 2002 and 2004, before de ESBL pandemic, showed that only 2% of those 
strains carried the CTX-M-15 gene [55]; almost two decades later, ST131 is one of 
the main clones isolated in the worldwide spread of ESBL-producing E. coli [56], 
particularly subclone H30Rx [57]. How this E. coli clone went from being a non-
factor in the global ESBL transmission to a key player is probably multifactorial. 
Although ST131 strains are not considered hypervirulent, most of them show the 
presence of fluoroquinolone-resistant genes, they have the ability to be persistent 
gut colonizers even in the absence of antibiotic exposure, a condition that precedes 
some infections such as those in the urinary tract, and can be easily transmitted 
between people of all ages [58]. All of these factors have allowed this clone to be 
successful human pathogen, even before the spread of the ESBL genes; however, the 
acquisition by ST131 strains of the CTX-M-15 plasmid has made this E. coli lineage 
an even more successful pathogen and has probably exasperated the spread of such 
clone [59] and the rapid global spread of CTX-M-15-producing E. coli.
3.1.2 AmpC β-lactamases (AmpC)
Although the production of class A extended spectrum β-lactamases is the 
most common mechanism of resistance in E. coli against β-lactam agents, class C 
β-lactamases, or AmpC, can also confer those strains that produce them the abil-
ity to inactivate some of these compounds. Similar to ESBL, AmpC-producing 
organisms hydrolyze amino- and ureidopenicillins, oxyimino-β-lactams such as 
ceftazidime, ceftiofur, and aztreonam, but contrary to the former enzymes, AmpC 
also inactivates broad and extended-spectrum cephalosporins such as cephamycins 
(cefoxitin) and are not inhibited by β-lactamase inhibitors such as clavulanic acid. 
Neither ESBL nor AmpC confer bacteria resistance to carbapenems.
Originally, AmpC were described as chromosomally encoded enzymes and were 
detected in a few bacterial species such as Enterobacter cloacae, Citrobacter freundii, 
Serratia marcescens, Acinetobacter spp., Aeromonas spp. and Pseudomonas aeruginosa 
[60]. As the use of β-lactamase inhibitors increased among the population, dissemi-
nation of AmpC genes among bacterial species began by means of horizontal travel 
through plasmids, phenomenon that led to the appearance of AmpC-resistant traits 
in bacteria that previously lacked such genes or expressed them at low levels, such 
as E. coli, Klebsiella spp. and Shigella spp. [60].
In E. coli, the subject of this chapter, resistance by AmpC can be plasmid 
encoded or due to the overexpression of the chromosomal AmpC genes. Contrary to 
the AmpC enzymes of other members of the Enterobacteriaceae, such as Enterobacter 
spp. and Citrobacter freundii, that of E. coli exhibits a non-inducible phenotype 
that is constitutive and its production depends on either the strength of the ampC 
promoter [61], the presence of >1 copy of the ampC gene, the incorporation of a 
stronger promoter sequence as part of an insertion element or by the acquisition of 
a strong promoter of other bacterial species [62]. As stated before, this organism 
can carry ampC genes either chromosomally or in plasmids; however, the latter 
is being recognized as the major threat since plasmid-encoded AmpC are easily 
transferable between bacterial species, can cause nosocomial outbreaks, is associ-
ated with multidrug resistance and, in combination with porin loss, may lead to 
resistance to carbapenems [63].
Bacterial resistance to β-lactams is a major public health problem around the 
world. Although ESBL production clearly exceeds AmpC production as the major 
cause of β-lactam resistance, the later enzymes are now being recognized as a 
growing problem in different members of the Enterobacteriaceae, including E. coli, as 
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evidenced by the increasing number of these strains being reported across the globe. 
Sources of AmpC-producing E. coli strains include livestock [64], the environment 
[65], as colonizers of the human gut [66] and as cause of human infections. The 
prevalence of these strains isolated as causative agents of human infections var-
ies, ranging from 2.0% reported in a Portuguese hospital [67] to 16.7% from three 
university hospitals in Iran [68] to 29.0% from five referral hospitals in Sudan [69].
When comparing the epidemiology of today’s AmpC-producing E. coli to that 
of ESBL-producing bacteria of two decades ago, they present several common 
features: high gut colonization in both animals and humans, reduced prevalence 
as cause of human infections, environmental contamination by these multidrug-
resistant strains, higher isolation of both types of β-lactamase-producing strains 
in developing countries and their ability to be transmitted via plasmids among 
different bacterial species. As these two types of β-lactamase-producing strains 
behave similarly, it would be of no surprise to witness in the near future a booming 
increase of reports of infections caused by AmpC-producing strains, as witness two 
decades ago with ESBL. To make matter worse, infectious disease specialists are 
starting to see an increase of cases of E. coli strains that co-express ESBL and AmpC 
genes, complicating antimicrobial treatment even further. Different reports in India 
[70, 71] have shown that co-expression of blaESBL and blaAmpC genes by E. coli 
strains isolated from different human infections is not uncommon, thus continu-
ous monitoring of these resistance patterns is a necessity that will help prevent the 
further spread of these multidrug-resistant microorganisms.
3.1.3 Carbapenemases
Since ESBL- and AmpC-producing E. coli are increasingly being reported as 
cause of severe infections, carbapenems represent in many cases the last option 
for effective treatment against these infections. Nevertheless, with an increasing 
consumption of these agents, carbapenem-resistant strains, particularly Klebsiella 
spp. and in a lesser degree E. coli, have become a public health concern, particularly 
in the hospital setting. Carbapenems bind to penicillin-binding proteins and induce 
spheroplast formation and cell lysis without filament formation. The carbapenems 
include four agents: imipenem, meropenem, ertapenem and doripenem.
As in the case of ESBL- and AmpC-producing Enterobacteriaceae, reports 
from different countries show that resistance to carbapenems has been constantly 
increasing in the last few years, becoming a public health problem. In Europe, 
11 countries have reported an increase in the number of infections caused by 
carbapenemase-producing Enterobacteriaceae in the period from 2015 to 2018 
[72] and in China, Tian et al. [73] have reported an increase in the prevalence of 
carbapenemase-producing E. coli from 0% in 2011 to 1.9% in 2017.
The reported carbapenemases in E. coli primarily include Klebsiella pneumoniae 
carbapenemases (KPC), metallo-β-lactamases (MBL), including the VIM, IMP, 
GIM and NDM type, and oxacillin-hydrolyzing metallo-β-lactamases (OXA) [74]; 
however, different reports around the world have shown that the predominant 
types in E. coli are of the New Delhi metallo-β-lactamase (NDM-1) and carbape-
nem-hydrolyzing oxacillinase-48 (OXA-48) types [73, 75, 76].
3.1.3.1 New Delhi metallo-β-lactamase
The New Delhi metallo-β-lactamase (NDM-1) and closely related enzymes are a 
group of zinc-requiring metallo-β-lactamases capable of hydrolyzing a broad range 
of β-lactams including all penicillins, cephalosporins and carbapenems, just sparing 
monobactams, and are among the most recently identified carbapenemases. The 
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gene encoding these enzymes, blaNDM, has been identified on bacterial chromo-
somes and plasmids [77]; however, in the case of E. coli, blaNDM is mainly plasmid 
encoded with only few strains carrying it chromosomally [78].
NDM-1 was first identified in 2008 in India, a country that has been pointed 
out as the primary reservoir of NDM strains [77], followed by the Balkan states 
[79] and the Middle East [80]. From these three spots, blaNDM-1-carrying bacterial 
strains have spread around the world, mainly due to the ability of the carrying 
microorganisms to horizontally transfer the carbapenemase resistance trait via 
plasmids. An additional factor that has contributed to the worldwide dissemination 
of NDM-1-producing strains is the frequent co-existence of the blaNDM-1 gene on 
plasmids carrying additional antibiotic resistance genes, situation that has allowed 
the plasmid-carrying strains to thrive under environments of antibiotic selective 
pressure.
Since the first report of NDM-1, over 20 NDM variants have been reported; 
however, in E. coli, NDM-1, followed by NDM-5, are the predominant variants in 
human infections in different parts of the world [81, 82]. Surprisingly, in a study 
by Shen et al. [83] published in 2018, the highest prevalence in the human gut and 
livestock was of the NMD-5 variant, suggesting a possible shift from NDM-1 to 
NDM-5 in the community in China. An additional, and important finding of this 
study, was the identification, albeit small, of NDM-5 E. coli strains that co-express 
colistin resistance genes, mcr-1, in the gut of healthy individuals, situation that 
if not properly controlled might contribute to the future dissemination of E. coli 
strains that are resistant to last resource antibiotics.
3.1.3.2 Carbapenem-hydrolyzing oxacillinase-48 (OXA-48)
As with any other β-lactamase, OXA-48 hydrolyzes β-lactam antibiotics, includ-
ing carbapenemases, but paradoxically spares broad-spectrum cephalosporins. 
OXA-48 genes were originally traced to the aquatic bacterium Shewanella oneidensis, 
but further studies now trace its origin to Shewanella xiamenensis [84]. Since the 
first description in Europe of OXA-48-carrying Enterobacteriaceae, several variants 
have been reported, including OXA-162, OXA-163, OXA-181, OXA-204, OXA-232, 
OXA244 and OXA-245.
Mainly found in Klebsiella species, reports on the detection of blaoxa-carrying E. 
coli have increased in the last 3 years in different parts of the world, being reported 
in studies in Myanmar [85], the United States [86] and Thailand [87]. In all three 
studies, the isolated strains were co-expressing blaOXA-48 or its variants and blaNDM5. 
Oxa-48-carrying E. coli strains have also been isolated in Europe, between January 
and October 2019, 134 cases of E. coli strains carrying the OXA-48 variant OXA-
244 were isolated from clinical samples in Germany; this same variant was further 
identified in 119 E. coli strains isolated from other European countries [88]. The 
source and route of transmission of these strains is currently unclear.
As carbapenems are considering in many clinical instances as a last resource 
antibiotic, worldwide monitoring on the prevalence of E. coli carrying resistant 
traits against these agents should be continuously performed in order to prevent 
the spread of these strains, situation that can jeopardize even further the current 
antibiotic resistance crisis.
4. Conclusions
The ability of Escherichia coli to colonize the gut of humans and animals, thus 
facilitating its transmission via the fecal-oral route, and its ability to transmit and 
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uptake antibiotic resistance genes via plasmids to and from other bacteria have 
made this organism a key target in the fight against antimicrobial resistance. As 
discussed in this chapter, E. coli has evolved different mechanisms to fight off the 
action of antibiotics, and in many cases a single strain can carry resistance genes to 
distinct classes of these agents, thus complicating treatment.
The emergence of antibiotic resistance has been shown to be multifactorial, but 
all elements coincide in a major topic: antibiotic over abuse, both in human and 
veterinary medicine. The establishment of antibiotic stewardship programs is a 
major necessity in all nations as a way to reduced antibiotic resistance. However, as 
the spread and maintenance of E. coli-resistant traits among humans and between 
animals and humans is driven by additional, and probably more difficult to tackle, 
social issues such as lack of hygiene, lack of drinking water and house overcrowd-
ing, these factors must be taken care of in order to truly impact antibiotic resistance.
Conflict of interest
The author declares no conflict of interest.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Please use Adobe A robat Reader to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...A robat is locking documen loading.com
r
File cannot be found.
14
E. Coli Infections - Importance of Early Diagnosis and Efficient Treatment
[1] Riley M, Abe T, Arnaud MB, 
Berlyn MK, Blattner FR, Chaudhuri RR, 
et al. Escherichia coli K-12: A cooperatively 
developed annotation snapshot—2005. 
Nucleic Acids Research. 2006;34:1-9. 
DOI: 10.1093/nar/gkj405
[2] Hewitt JH, Rigby J. Effect of various 
milk feeds on numbers of Escherichia 
coli and Bifidobacterium in the stools of 
new-born infants. Journal of Hygiene 
(London). 1976;77(1):129-139. DOI: 
10.1017/s0022172400055601
[3] Mohr K. History of antibiotics 
research. Current Topics in 
Microbiology and Immunology. 
2016;398:237-272. DOI: 10.1007/ 
82_2016_499
[4] Lowy FD. Antimicrobial resistance: 
The example of Staphylococcus aureus. 
The Journal of Clinical Investigation. 
2003;111(9):1265-1273. DOI: 10.1172/
JCI18535
[5] World Health Organization. WHO 
Publishes List of Bacteria for Which 
New Antibiotics Are Urgently Needed. 
2017. Available from: https://www.who.
int/news-room/detail/27-02-2017-who-
publishes-list-of-bacteria-for-which-
new-antibiotics-are-urgently-needed 
[Accessed: 09 April 2020]
[6] Tadesse DA, Zhao S, Tong E,  
Ayers S, Singh A, Bartholomew MJ. 
Antimicrobial drug resistance in 
Escherichia coli from humans and food 
animals, United States, 1950-2002.  
Emerging Infectious Diseases. 
2012;18(5):741-749. DOI: 10.3201/
eid1805.111153
[7] Ny S, Edquist P, Dumpis U, 
Gröndahl-Yli-Hannuksela K, 
Hermes J, Kling AM, et al. Antimicrobial 
resistance of Escherichia coli isolates 
from outpatient urinary tract infections 
in women in six European countries 
including Russia. Journal of Global 
Antimicrobial Resistance. 2019;17: 
25-34. DOI: 10.1016/j.jgar.2018.11.004
[8] World Health Organization. WHO 
Report on Surveillance of Antibiotic 
Consumption. 2018. Available from: 
https://apps.who.int/iris/bitstream/han
dle/10665/277359/9789241514880-eng.
pdf [Accessed: 09 April 2020]
[9] Sommer MO, Dantas G, Church GM.  
Functional characterization of the 
antibiotic resistance reservoir in 
the human microflora. Science. 
2009;325(5944):1128-1131. DOI: 
10.1126/science.1176950
[10] Cox G, Wright GD. Intrinsic 
antibiotic resistance: Mechanisms, 
origins, challenges and solutions. 
International Journal of Medical 
Microbiology. 2013;303(6-7):287-292. 
DOI: 10.1016/j.ijmm.2013.02.009
[11] Liu A, Tran L, Becket E, Lee K,  
Chinn L, Park E, et al. Antibiotic 
sensitivity profiles determined with 
an Escherichia coli gene knockout 
collection: Generating an antibiotic 
bar code. Antimicrobial Agents and 
Chemotherapy. 2010;54:1393-1403. 
DOI: 10.1128/AAC.00906-09
[12] Nikaido H, Rosenberg EY, 
Foulds J. Porin channels in Escherichia 
coli: Studies with beta-lactams in 
intact cells. Journal of Bacteriology. 
1983;153(1):232-240. DOI: 10.1128/
JB.153.1.232-240.1983
[13] European Centre for Disease 
Prevention and Control. Surveillance 
of Antimicrobial Resistance in Europe. 
2018. Available from: https://www.
ecdc.europa.eu/en/publications-data/
surveillance-antimicrobial-resistance-
europe-2018 [Accessed: 10 April 2020]
[14] Critchley I, Cotroneo N, Pucci M, 
Mendes R. The burden in antimicrobial 
resistance among urinary tract isolates 
References
Pleas  use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Co nect on...Ac obat is ocki g documen loading.com
r
File cannot be found.
15
Antimicrobial Resistance in Escherichia coli
DOI: http://dx.doi.org/10.5772/intechopen.93115
in Escherichia coli in the United States in 
2017. PLoS One. 2019;14(12):e0220265. 
DOI: 10.1371/journal.pone.0220265
[15] Garza-Gonzalez E, Morfın-Otero R, 
Mendoza-Olazara S, Bocanegra- 
Ibarias S, Flores-Treviño S, Rodrıguez- 
Noriega E, et al. A snapshot of 
antimicrobial resistance in Mexico. 
Results from 47 centers from 20 states 
during a six-month period. PLoS One. 
2019;14(3):e0209865. DOI: 10.1371/
journal.pone.0209865
[16] Huan Y, Oguto JO, Gu J, Ding F, 
You Y, Huo Y, et al. Comparative analysis 
of quinolone resistance in clinical 
isolates of Klebsiella pneumoniae 
and Escherichia coli from Chinese 
children and adults. BioMed Research 
International Journal. 2015;168292. 
DOI: 10.1155/2015/168292
[17] Cöplü N, Simsek H, Gür D, 
Gözalan A, Hasdemir U, Gülay Z. The 
first results of national antimicrobial 
resistance surveillance system in Turkey. 
Türk Hijiyen ve Tecrübi Biyoloji Dergisi. 
2018;75(4):333-344. DOI: 10.5505/
TurkHijyen.2018.68878
[18] Read AF, Woods RJ. Antibiotic 
resistance management. Evolution, 
Medicine, and Public Health. 
2014;2014(1):147. DOI: 10.1093/emph/
eou024
[19] World Health Organization. 
Antimicrobial Resistance. Available 
from: https://www.who.int/health-
topics/antimicrobial-resistance 
[Accessed: 10 April 2020]
[20] Kolar M, Urbánek K, Látal T.  
Antibiotic selective pressure and 
development of bacterial resistance. 
International Journal of Antimicrobial 
Agents. 2001;17(5):357-363. DOI: 
10.1016/s0924-8579(01)00317-x
[21] Klein EY, Van Boeckel TP,  
Martinez EM, Pant S, Gandra S, 
Levin SA, et al. Global increase and 
geographic convergence in antibiotic 
consumption between 2000 and 2015. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2018;115(15):E3463-E3470. 
DOI: 10.1073/pnas.1717295115
[22] Nordmann P, Poirel L. Epidemiology 
and diagnostics of carbapenem 
resistance in Gram-negative bacteria. 
Clinical Infectious Diseases. 
2019;69(7):S521-S528. DOI: 10.1093/cid/
ciz824
[23] Nordmann P, Poirel L. Strategies 
for identification of carbapenemase-
producing Enterobacteriaceae. The 
Journal of Antimicrobial Chemotherapy. 
2013;68:487-489. DOI: 10.1093/jac/
dks426
[24] Shively NR, Buehrle DJ, Clancy CJ, 
Decker BK. Prevalence of inappropriate 
antibiotic prescribing in primary care 
clinics within a veterans affairs health 
care system. Antimicrobial Agents and 
Chemotherapy. 2018;62(8):e00337-18. 
DOI: 10.1128/AAC.00337-18
[25] Zhang L, Levy K, Trueba G, 
Cevallos W, Trostle J, Foxman B. Effects 
of selection pressure and genetic 
association on the relationship between 
antibiotic resistance and virulence in 
Escherichia coli. Antimicrobial Agents 
and Chemotherapy. 2015;59(11):6733-
6740. DOI: 10.1128/AAC.01094-15
[26] McEwen SA, Fedorka-Cray PJ. 
Antimicrobial use and resistance in 
animals. Clinical Infectious Diseases. 
2002;34(Suppl 3):S93-S106. DOI: 
10.1086/340246
[27] Kaesbohrer A, Bakran-Lebl K, 
Irrgang A, Fischer J, Kämpf P, 
Schiffmann A. Diversity in prevalence 
and characteristics of ESBL/pAmpC 
producing E. coli in food in Germany. 
Veterinary Microbiology. 2019;233:52-
60. DOI: 10.1016/j.vetmic.2019.03.025
[28] Galindo-Méndez M. Reservoirs 
of CTX-M extended spectrum 
Please use Adobe A robat Reader to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...A robat is locking documen loading.com
r
File cannot be found.
E. Coli Infections - Importance of Early Diagnosis and Efficient Treatment
16
β-lactamase-producing 
Enterobacteriaceae in Oaxaca, 
Mexico. Journal of Microbiology & 
Experimentation. 2019;7(1):43-47.  
DOI: 10.15406/jmen.2019.07.00239
[29] Köck R, Daniels-Haardt I, 
Becker K, Mellmann A, Friedrich AW, 
Mevius D. Carbapenemase-resistant 
Enterobacteriaceae in wildlife, food-
producing, and companion animals: A 
systematic review. Clinical Microbiology 
and Infection. 2018;24(12):1241-1250. 
DOI: 10.1016/j.cmi.2018.04.004
[30] Joshi PR, Thummeepak R, 
Leugtongkam U, Pooarlai R, 
Paudel S, Acharya M, et al. The 
emergence of colistin-resistant 
Escherichia coli in chicken meats in 
Nepal. FEMS Microbiology Letters. 
2019;366(20):fnz237. DOI: 10.1093/
femsle/fnz237
[31] Ruppé E, Lixandru B, Cojocaru R, 
Buke C, Paramythiotou E, 
Angebault C, et al. Relative fecal 
abundance of extended-spectrum-
β-lactamase-producing Escherichia 
coli strains and their occurrence 
in urinary tract infections in 
women. Antimicrobial Agents and 
Chemotherapy. 2013;57(9):4512-4517. 
DOI: 10.1128/AAC.00238-13
[32] Collignon P, Beggs JJ, Walsh TR,  
Gandra S, Laxminarayan R. 
Anthropological and socioeconomic 
factors contributing to global 
antimicrobial resistance: A univariate 
and multivariable analysis. The Lancet 
Planetary Health. 2018;2:e398-e405. 
DOI: 10.1016/S2542-5196(18)30186-4
[33] Hu Y, Yang X, Qin J, Lu N, Cheng G, 
Wu N. Metagenome-wide analysis of 
antibiotic resistance genes in a large 
cohort of human gut microbiota. Nature 
Communications. 2013;4:2151. DOI: 
10.1038/ncomms3151
[34] Canton R, Coque TM. The CTX-M 
β-lactamase pandemic. Current Opinion 
in Microbiology. 2006;9(5):466-475. 
DOI: 10.1016/j.mib.2006.08.011
[35] Poirel L, Potron A, Nordmann P. 
OXA-48-like carbapenemases: The 
phantom menace. The Journal of 
Antimicrobial Chemotherapy. 
2012;67(7):1597-1606. DOI: 10.1093/jac/
dks121
[36] von Wintersdorff CJH, Penders J,  
van Niekerk JM, Mills ND,  
Majumder S, van Alphen LV. 
Dissemination of antimicrobial resistance 
in microbial ecosystems through 
horizontal gene transfer. Frontiers in 
Microbiology. 2016;7:173. DOI: 10.3389/
fmicb.2016.00173
[37] Ye Q , Wu Q , Zhang S, Zhang J, 
Yang G, Wang J, et al. Characterization 
of extended-Spectrum β-lactamase-
producing Enterobacteriaceae from 
retail food in China. Frontiers in 
Microbiology. 2018;9:1709. DOI: 
10.3389/fmicb.2018.01709
[38] Prelog M, Grif K, Decristoforo C, 
Wurzner R, Kiechl-Kohlendorfer U, 
Brunner A, et al. Tetracycline-resistant 
Escherichia coli strains are inherited 
from parents and persist in the 
infant’s intestines in the absence of 
selective pressure. European Journal 
of Pediatrics. 2009;168(10):1181-1187. 
DOI: 10.1007/s00431-008-0901-0
[39] Bryce A, Costelloe C, Hawcroft C, 
Wootton M, Hay AD. Faecal carriage 
of antibiotic resistant Escherichia coli in 
asymptomatic children and associations 
with primary care antibiotic 
prescribing: A systematic review 
and meta-analysis. BMC Infectious 
Diseases. 2016;16:359. DOI: 10.1186/
s12879-016-1697-6
[40] Bourrel AS, Poirel L, Royer G, 
Darty M, Vuillemin X, Kieffer N, et al. 
Colistin resistance in Parisian inpatient 
faecal Escherichia coli as the result of 
two distinct evolutionary pathways. The 
Journal of Antimicrobial Chemotherapy. 
Pleas  use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Co nect on...Ac obat is ocki g documen loading.com
r
File cannot be found.
17
Antimicrobial Resistance in Escherichia coli
DOI: http://dx.doi.org/10.5772/intechopen.93115
2019;74(6):1521-1530. DOI: 10.1093/jac/
dkz090
[41] Merida-Vieyra J, De Colsa- 
Ranero A, Arzate-Barbosa P, Arias-de 
la Garza E, Méndez-Tenorio A, 
Murcia-Garzón J. First clinical 
isolate of Escherichia coli harboring 
mcr-1 gene in Mexico. PLoS One. 
2019;14(4):e0214648. DOI: 10.1371/
journal.pone.0214648. eCollection 2019
[42] Arcilla MS, van Hattem JM, 
Haverkate MR, Bootsma MCJ, van 
Genderen PJJ, Goorhuis A. Import 
and spread of extended-
spectrum β-lactamase-producing 
Enterobacteriaceae by international 
travellers (COMBAT study): A 
prospective, multicentre cohort 
study. The Lancet Infectious Diseases. 
2017;17(1):78-85. DOI: 10.1016/
S1473-3099(16)30319-X
[43] Valverde A, Grill F, Coque TM, 
Pintado V, Baquero F, Canton R, et al. 
High rate of intestinal colonization 
with extended spectrum-beta-
lactamase-producing organisms 
in household contacts of infected 
community patients. Journal of Clinical 
Microbiology. 2008;46(8):2796-2799. 
DOI: 10.1128/JCM.01008-08
[44] Lee K, Kim DW, Lee DH, Kim YS, 
Bu JH, Cha JH. Mobile resistome of 
human gut and pathogen drives 
anthropogenic bloom of antibiotic 
resistance. Microbiome. 2020;8(1):2. 
DOI: 10.1186/s40168-019-0774-7
[45] Bush K. Past and present 
perspectives on β-lactamases. 
Antimicrobial Agents and 
Chemotherapy. 2018;62(10):e01076-18. 
DOI: 10.1128/AAC.01076-18
[46] Bush K, Jacoby G. Updated 
functional classification of β 
lactamases. Antimicrobial Agents and 
Chemotherapy. 2010;54(3):969-976. 
DOI: 10.1128/AAC.01009-09
[47] Philippon A, Labia R, Jacoby G. 
Extended-spectrum beta-lactamases. 
Antimicrobial Agents and 
Chemotherapy. 1989;33:1131-1136. DOI: 
10.1128/aac.33.8.1131
[48] Bonnet R. Growing group of 
extended-spectrum β-lactamases: The 
CTX-M enzymes. Antimicrobial Agents 
and Chemotherapy. 2004;48(1):1-14. 
DOI: 10.1128/AAC.48.1.1-14.2004
[49] Liahopoulus A, Mevius D, 
Ceccarelli D. A review of SHV 
extended-spectrum β-lactamases: 
Neglected yet ubiquitous. Frontiers 
in Microbiology. 2016;7:1374. DOI: 
10.3389/fmicb.2016.01374
[50] Paterson DL, Bonomo RA. 
Extended-spectrum β-lactamases: A 
clinical update. Clinical Microbiology 
Reviews. 2005;18(4):657-686. DOI: 
10.1128/CMR.18.4.657-686.2005
[51] Cantón R, Ruiz-Garbajosa P. 
Co-resistance: An opportunity for the 
bacteria and resistance genes. Current 
Opinion in Pharmacology. 2011;11:477-
485. DOI: 10.1016/j.coph.2011.07.007
[52] Boyd DA, Tyler S, Christianson S, 
McGeer A, Muller MP, Willey BM, 
et al. Complete nucleotide sequence of 
a 92-kilobase plasmid harboring the 
CTX-M-15 extended-spectrum beta-
lactamase involved in an outbreak in 
long-term-care facilities in Toronto, 
Canada. Antimicrobial Agents and 
Chemotherapy. 2004;48(10):3758-3764. 
DOI: 10.1128/AAC.48.10.3758-3764.2004
[53] Ramadan A, Abdelaziz NA, 
Amin NA, Aziz RK. Novel blaCTX-M 
variants and genotype-phenotype 
correlations among clinical isolates of 
extended spectrum beta lactamase-
producing Escherichia coli. Scientific 
Reports. 2019;9(1):4224. DOI: 10.1038/
s41598-019-39730-0
[54] Bevan ER, Jones AM, 
Hawkey PM. Global epidemiology of 
Please use Adobe A robat Reader to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...A robat is locking documen loading.com
r
File cannot be found.
E. Coli Infections - Importance of Early Diagnosis and Efficient Treatment
18
CTX-M β-lactamases: Temporal and 
geographical shifts in genotype. Journal 
of Antimicrobial Chemotherapy. 
2017;72(8):2145-2155. DOI: 10.1093/jac/
dkx146
[55] Johnson JR, Menard M, 
Johnston B, Kuskowski MA, Nichol K, 
Zhanel GG. Epidemic clonal groups 
of Escherichia coli as a cause of 
antimicrobial-resistant urinary 
tract infections in Canada, 2002 to 
2004. Antimicrobial Agents and 
Chemotherapy. 2009;53:2733-2739. DOI: 
10.1128/AAC.00297-09
[56] Rogers BA, Sidjabat HE,  
Paterson DL. Escherichia coli 
O25b-ST131: A pandemic, 
multiresistant, community-associated 
strain. The Journal of Antimicrobial 
Chemotherapy. 2011;66(1):1-14. DOI: 
10.1093/jac/dkq415
[57] Nicolas-Chanoine MH, 
Bertrand X, Madec JY. Escherichia coli 
ST131, an intriguing clonal group. 
Clinical Microbiology Reviews. 
2014;27(3):543-574. DOI: 10.1128/
CMR.00125-13
[58] Whitmer GR, Moorthy G, 
Arshad M. The pandemic Escherichia coli 
sequence type 131 strain is acquired even 
in the absence of antibiotic exposure. 
PLoS Pathogens. 2019;15(12):e1008162. 
DOI: 10.1371/journal.ppat.1008162
[59] Peirano G, Pitout JDD. Molecular 
epidemiology of Escherichia coli 
producing CTX-M β-lactamases: 
The worldwide emergence of 
clone ST131 O25:H4. International 
Journal of Antimicrobial Agents. 
2010;35(4):316-321. DOI: 10.1016/j.
ijantimicag.2009.11.003
[60] Beceiro A, Bou G. Class 
β-lactamases: An increasing problem 
worldwide. Reviews in Medical 
Microbiology. 2004;15(4):141-152. DOI: 
10.1097/00013542-200410000-00003
[61] Caroff N, Espaze E, Gautreau D, 
Richet H, Reynaud A. Analysis of the 
effects of -42 and -32 ampC promoter 
mutations in clinical isolates of 
Escherichia coli hyperproducing 
AmpC. The Journal of Antimicrobial 
Chemotherapy. 2000;45(6):783-788. 
DOI: 10.1093/jac/45.6.783
[62] Jaurin B, Normark S.  
Insertion of IS2 creates a novel 
ampC promoter in Escherichia coli. 
Cell. 1983;32(3):809-816. DOI: 
10.1016/0092-8674(83)90067-3
[63] Matsumura Y, Tanaka M, 
Yamamoto M, Nagao M, Machida K, 
Ito Y, et al. High prevalence of 
carbapenem resistance among plasmid-
mediated AmpC beta-lactamase-
producing Klebsiella pneumoniae during 
outbreaks in liver transplantation units. 
International Journal of Antimicrobial 
Agents. 2015;45(1):33-40. DOI: 
10.1016/j.ijantimicag.2014.08.015
[64] Vounba P, Arsenault J, 
Bada-Alambédji R, Fairbrother JM. 
Antimicrobial resistance and potential 
pathogenicity of Escherichia coli isolates 
from healthy broilers in Québec, 
Canada. Microbial Drug Resistance. 
2019;25(7):1111-1121. DOI: 10.1089/
mdr.2018.0403
[65] Sen K, Berglund T, Soares MA, 
Taheri M, Ma Y, Khalil L, et al. 
Antibiotic resistance of E. coli isolated 
from a constructed wetland dominated 
by a crow roost, with emphasis on ESBL 
and AmpC containing E. coli. Frontiers 
in Microbiology. 2019;10:1034. DOI: 
10.3389/fmicb.2019.01034
[66] Nakayama T, Kumeda Y, Kawahara R, 
Yamamoto Y. Quantification and long-
term carriage study of human extended 
spectrum/AmpC β-lactamase-producing 
Escherichia coli after international 
travel to Vietnam. Journal of Global 
Antimicrobial Resistance. 2019;21:229-
234. DOI: 10.1016/j.jgar.2019.11.001
Pleas  use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Co nect on...Ac obat is ocki g documen loading.com
r
File cannot be found.
19
Antimicrobial Resistance in Escherichia coli
DOI: http://dx.doi.org/10.5772/intechopen.93115
[67] Oliveira C, Amador P, Prudencio C, 
Tomaz CT, Tavarez-Ratado P, 
Fernander R. ESBL and AmpC 
β-lactamases in clinical strains of 
Escherichia coli from Serra da Estrela, 
Portugal. Medicina (Kaunas, Lithuania) 
2019;55(6):pii: E272. DOI: 10.3390/
medicina55060272
[68] Rizi KS, Mosavat A, Youssefi M, 
Jamehdar SA, Ghazyini K, Safdari H, 
et al. High prevalence of blaCMY AmpC 
Beta-lactamase in ESBL co-producing 
Escherichia coli and Klebsiella spp. clinical 
isolates in northeast of Iran. Journal 
of Global Antimicrobial Resistance. 
2020;S2213-7165(20):30075-8. DOI: 
10.1016/j.jgar.2020.03.011. [Published 
online ahead of print, 01 Apr 2020]
[69] Dirar M, Bilal N, Ibrahim ME, 
Hamid M. Resistance patterns and 
phenotypic detection of β-lactamase 
enzymes among Enterobacteriaceae 
isolates from referral hospitals in 
Khartoum State, Sudan. Cureus. 
2020;12(3):e7260. DOI: 10.7759/
cureus.7260
[70] Ghosh B, Mukherjee M. Emergence 
of co-production of plasmid mediated 
AmpC beta-lactamase and ESBL in 
cefoxitin-resistant uropathogenic 
Escherichia coli. European Journal of 
Clinical Microbiology & Infectious 
Diseases. 2016;35(9):1449-1454. DOI: 
10.1007/s10096-016-2683-z
[71] Mirza S, Jadhav S, Misra RN, 
Das NK. Coexistence of β-lactamases 
in community-acquired infections 
in tertiary care hospital in 
India. International Journal of 
Microbiology. 2019;2019:7019578. 
DOI:10.1155/2019/7019578
[72] Brolund A, Lagerqvist N, Byfors S,  
Struelens MJ, Monnet DL, Albiger B,  
et al. Worsening epidemiological 
situation of carbapenemase-producing 
Enterobacteriaceae in Europe, assessment 
by national experts from 37 countries, 
July 2018. Journal of Euro Surveillance. 
2019;24(9):1900123. DOI: 10.2807/1560-
7917. ES.2019.24.9.1900123
[73] Tian X, Zheng X, Sun Y, Fang R, 
Zhang S, Zhang X, et al. Molecular 
mechanisms and epidemiology of 
carbapenem-resistant Escherichia 
coli isolated from Chinese patients 
during 2002-2017. Infection and Drug 
Resistance. 2020;13:501-512. DOI: 
10.2147/IDR.S232010
[74] Nordmann P, Naas T, Poirel L.  
Global spread of carbapenemase-
producing Enterobacteriaceae. Emerging 
Infectious Diseases. 2011;17:1791-1798. 
DOI: 10.3201/eid1210.110655
[75] Gauthier L, Dortet L, Cotellon G, 
Creton E, Cuzon G, Ponties V, et al. 
Diversity of carbapenemase-producing 
Escherichia coli isolates in France in 
2012-2013. Antimicrobial Agents and 
Chemotherapy. 2018;62(8):e00266-18. 
DOI: 10.1128/AAC.00266-18
[76] Nordmann P, Poirel L. The difficult-
to-control spread of carbapenemase 
producers among Enterobacteriaceae 
worldwide. Clinical Microbiology and 
Infection. 2014;20(9):821-830. DOI: 
10.1111/1469-0691.12719
[77] Kumarasamy KK, Toleman MA, 
Walsh TR, Bagaria J, Butt F, 
Balakrishnan R, et al. Emergence of 
a new antibiotic resistance 
mechanism in India, Pakistan and 
the UK: A molecular, biological and 
epidemiological study. The Lancet 
Infectious Diseases. 2010;10(9):597-602. 
DOI: 10.1016/S1473-3099(10)70143-2
[78] Shen P, Yi M, Fu Y, Ruan Z, Du X, 
Yu Y, et al. Detection of an Escherichia 
coli sequence type 167 strain with 
two tandem copies of blaNDM-1 in 
the chromosome. Journal of Clinical 
Microbiology. 2016;551(1):199-205. 
DOI: 10.1128/JCM.01581-16
[79] Zarfel G, Hoenigl M, Würstl B. 
Emergence of carbapenem-resistant 
Enterobacetriaceae in Austria, 
Please use Adobe A robat Reader to read this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...A robat is locking documen loading.com
r
File cannot be found.
E. Coli Infections - Importance of Early Diagnosis and Efficient Treatment
20
2001-2010. Clinical Microbiology and 
Infection. 2011;17(11):E5-E8. DOI: 
10.1111/j.1469-0691.2011.03659.x
[80] Shibl A, Al-Agamy M, Memish Z, 
Senok A, Khader SA, Assiri A. The 
emergence of OXA-48 and NDM-1-
positive Klebsiella pneumonia in Riyadh, 
Saudi Arabia. The Journal of Infectious 
Diseases. 2013;17(12):e1130-e1133. DOI: 
10.1016/j.ijid.2013.06.016
[81] Ranjan A, Shaik S, Mondal A, 
Nandanwar N, Hussain A, 
Semmler T, et al. Molecular 
epidemiology and genome dynamics 
of New Delhi metallo-beta-
lactamase-producing extraintestinal 
pathogenic Escherichia coli strains 
from India. Antimicrobial Agents and 
Chemotherapy. 2016;60(11):6795-6805. 
DOI: 10.1128/AAC.01345-16
[82] Hu X, Xu X, Wang X, Xue W, 
Zhou H, Zhang L, et al. Diversity of 
New Delhi metallo-beta-lactamase-
producing bacteria in China. 
International Journal of Infectious 
Diseases. 2017;55:92-95. DOI: 10.1016/j.
ijid.2017.01.011
[83] Shen Z, Hu Y, Sun Q , Hu F, 
Zhou H, Shu L, et al. Emerging carriage 
of NDM-5 and MCR-1 in Escherichia coli 
from healthy people in multiple regions 
in China: A cross sectional observational 
study. EClinicalMedicine. 2018;6:11-20. 
DOI: 10.1016/j.eclinm.2018.11.003
[84] Potron A, Poirel L, Nordmann P.  
Origin of OXA-181, an emerging 
carbapenem-hydrolyzing oxacillinase, 
as a chromosomal gene in Shewanella 
xiamenensis. Antimicrobial Agents and 
Chemotherapy. 2011;55(9):4405-4407. 
DOI: 10.1128/AAC.00681-11
[85] Aung MS, San N, Maw WW, San T, 
Urushibara N, Kawaguchiva M, et al. 
Prevalence of extended-spectrum beta-
lactamase and carbapenemase genes 
in clinical isolates of Escherichia coli in 
Myanmar: Dominance of blaNMD5 and 
emergence of blaOXA-181. Microbial Drug 
Resistance. 2018;24(9):1333-1344. DOI: 
10.1089/mdr.2017.0387
[86] Hasassri ME, Boyce TG, Norgan SA, 
Cunningham PR, Jeraldo S, Weissman S, 
et al. An immunocompromised child 
with bloodstream infection caused 
by two Escherichia coli strains, 
one harboring NDM-5 and the 
other harboring OXA-48-like 
carbapenemase. Antimicrobial Agents 
and Chemotherapy. 2016;60:3270-3275. 
DOI: 10.1128/AAC.03118-15
[87] Lunha K, Chanawong A, 
Lulitanond C, Wilailuckana N,  
Charoensri L, Wonglakorn P. High 
level carbapenem-resistant OXA-
48-producing Klebsiella pneumoniae 
with a novel OmpK36 variant and 
low-level, carbapenem-resistant, non-
porin-deficient, OXA-181-producing 
Escherichia coli from Thailand. 
Diagnostic Microbiology and Infectious 
Disease. 2016;85:221-226. DOI: 
10.1016/j.diagmicrobio.2016.03.009
[88] European Centre for Disease 
Prevention and Control. Increase in 
OXA-244-Producing Escherichia coli 
in the European Union/European 
Economic Area and the UK since 
2013. 2020. Available from: https://
www.ecdc.europa.eu/sites/default/
files/documents/RRA-E-coli-OXA-
244-producing-E-coli-EU-EEA-UK-
since-2013.pdf [Accessed: 15 April 
2020]
Pleas  use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Co nect on...Ac obat is ocki g documen loading.com
r
File cannot be found.
